Navigation Links
Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
Date:1/16/2012

AUSTIN, Texas, Jan. 16, 2012 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the fourth quarter and full year 2011 on Monday, February 6, 2012. A press release announcing the results is scheduled for release after the close of trading.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Management will hold a conference call to discuss the operating highlights and financial results for the fourth quarter and full year ended December 31, 2011, on February 6, 2012, at 5:00 p.m. Eastern time.

The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

The use of pop-up blocking software may impair your ability to view webcasts. If you use this software, press and hold the CTRL key when you click on the Register button. Please contact your IT group if you are unable to override this feature. Unauthorized recording or downloading of this event is not permitted.

About Luminex Corporation

Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com.

Statements made in this release that express Luminex Corporation's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Luminex Corporate Contact:

Harriss T. Currie
Chief Financial Officer and Vice President, Finance
512-219-8020
hcurrie@luminexcorp.com

Luminex Investor Relations Contact:

Matthew D. Scalo
Sr. Director of Investor Relations
512-219-8020
mscalo@luminexcorp.com


'/>"/>
SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Luminex Corporation to Present at JP Morgan Healthcare Conference
2. Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match®
3. Neogen Corporation Announces 2nd Quarter Results Conference Call
4. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
5. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
6. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
7. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
8. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
9. China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 19, 2011
10. China Cord Blood Corporation Files Its Annual Report on Form 20-F
11. McKesson Corporation Unveils New Offerings to Empower the Community Patient Care Delivery System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, NC 501(c)3 ... mission is to advance global health and highlight the greater good of clinical trial ... clinical trial volunteer. The vision of GGI is to serve as a philanthropic connector ...
(Date:2/23/2017)... DIEGO and SAN FRANCISCO ... a privately-held regenerative medicine company, and Beyond Type 1, ... with type 1 diabetes, today announced a grant from ... a functional cure for type 1 and other insulin-requiring ... ViaCyte has been developing innovative stem cell-derived cell replacement ...
(Date:2/22/2017)... ... 22, 2017 , ... Kernel , a human intelligence ... (KRS) clinical development program. KRS is a neurotechnology spin-out from the Massachusetts ... applications. The terms of the transaction were not disclosed. , It addition ...
(Date:2/22/2017)... 22, 2017 Scientists propose in Nature ... damage in Gaucher and maybe other lysosomal storage diseases ... costs than current therapies. An international research ... , which also included investigators from the University of ... data Feb. 22. The study was conducted in mouse ...
Breaking Biology Technology:
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
(Date:1/26/2017)... 26, 2017  Crossmatch, a leading provider of security ... aimed at combatting fraud, waste and abuse in assistance ... the Action on Disaster Relief conference in ... UN agencies and foreign assistance organizations throughout ... abuse are a largely unacknowledged problem in the foreign ...
Breaking Biology News(10 mins):